00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
22:38 , Mar 19, 2019 |  BC Extra  |  Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
20:27 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

Basilea Pharmaceutica Ltd. (SIX:SLN) reported interim data from the pivotal Phase II ARQ 087-301 trial to treat intrahepatic cholangiocarcinoma showing derazantinib led to an objective response rate (ORR) of 21% and a disease control rate...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
17:21 , Jul 20, 2018 |  BC Week In Review  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on July 17. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm CITICPE,...
21:55 , Jul 17, 2018 |  BC Extra  |  Company News

Roivant's China biotech reveals pipeline, pair of deals

Sinovant Sciences Ltd. (Shanghai, China) unveiled its pipeline, which contains four Phase III-ready assets, along with two new partnerships on a newsy Tuesday. Backed by Roivant Sciences GmbH (Basel, Switzerland) and Chinese private equity firm...
19:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

ArQule raises $69.6M follow-on

Cancer and rare disease company ArQule Inc. (NASDAQ:ARQL) raised $69.6 million through the sale of 12.7 million shares at $5.50 in a follow-on underwritten by Leerink, Needham, Roth Capital, B. Riley FBR and JonesTrading. The...
22:48 , May 25, 2018 |  BC Extra  |  Company News

Management tracks: ISA, ImCheck, ArQule

Immunotherapy company ISA Pharmaceuticals B.V. (Leiden, the Netherlands) promoted CBO Gerben Moolhuizen to CEO, effective June 1. He succeeds CEO Ronald Loggers. Also in May, ISA hired Leon Hooftman as CMO. Hooftman was CMO at...
19:08 , Apr 20, 2018 |  BC Week In Review  |  Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong and Macau. Derazantinib is a pan-fibroblast growth factor (FGF) receptor...
19:09 , Apr 17, 2018 |  BC Extra  |  Company News

Basilea gains rights to ArQule's derazantinib

ArQule Inc. (NASDAQ:ARQL) shares rose $0.46 (17%) to $3.16 on Tuesday after it granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong...